Inotiv, Inc. (NOTV)
| Market Cap | 83.47M |
| Revenue (ttm) | 501.06M |
| Net Income (ttm) | -99.22M |
| Shares Out | 26.00M |
| EPS (ttm) | -3.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,288,936 |
| Open | 3.150 |
| Previous Close | 2.790 |
| Day's Range | 3.100 - 3.780 |
| 52-Week Range | 1.230 - 11.420 |
| Beta | 3.37 |
| Analysts | Strong Buy |
| Price Target | 5.92 (+84.42%) |
| Earnings Date | Dec 3, 2024 |
About NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company’s BASi product line. The RMS segment engages in commercial p... [Read more]
Financial Performance
In 2023, Inotiv's revenue was $572.43 million, an increase of 4.52% compared to the previous year's $547.66 million. Losses were -$105.14 million, -68.80% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NOTV stock is "Strong Buy." The 12-month stock price forecast is $5.92, which is an increase of 84.42% from the latest price.
News
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dru...
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development ...
Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief ...
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv, Inc. Provides Business Updates
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dru...
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare
Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery a...
Inotiv, Inc. (NOTV) Q2 2024 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV) Q2 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and CEO Beth Taylor - Chief Financial O...
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update
— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on r...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024
WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dru...
Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results
WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery a...
INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024
WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical d...
INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
NEW ORLEANS, La. , April 19, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Inotiv, Inc. (NOTV) Q1 2024 Earnings Call Transcript
Inotiv, Inc. (NOTV) Q1 2024 Earnings Call Transcript
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
- First quarter fiscal 2024 revenue up 10.3% to $135.5 million - First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million - Shift to a renewed focus on ...
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical dr...
Inotiv: The Business Is Recovering, The Stock Will Follow
NOTV stock has significantly dropped due to a supply chain shock, but the current price remains far below its estimated fair value. The company's fundamental recovery is in place, with strong financia...
Inotiv, Inc. (NOTV) Q4 2023 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV) Q4 2023 Earnings Conference Call December 11, 2023 4:30 PM ET Company Participants Bob Yedid - LifeSci Advisors, Investor Relations Bob Leasure - Chief Executive Officer, P...
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing exp...
Inotiv, Inc. Announces Plan to Insource North American Transportation Operations
WEST LAFAYETTE, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023
WEST LAFAYETTE, Ind., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and a...
Inotiv Provides Business Updates and Upcoming Investor Conferences Update
WEST LAFAYETTE, Ind., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development ...
Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint Attributes 1156% Revenue Growth to Addi...